Latest News and Press Releases

ARU-1801 reduced vaso-occlusive events and days in the hospital for patients with severe sickle cell disease MILLBURN, N.J. and BASEL, Switzerland, May 16, 2022 (GLOBE NEWSWIRE) -- Aruvant Sciences...

Dr. Srini Ramanathan has over 20 years of experience in drug development and joins Roivant from Horizon Therapeutics where he built scientific R&D capabilities and teams to advance the company’s...

Tapinarof demonstrated continued improvements for up to 52 weeks in efficacy outcomes, quality of life measures, and tolerability scores with no associated tachyphylaxisTapinarof was well-tolerated in...

BASEL, Switzerland and LONDON and NEW YORK and BOSTON, March 11, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) today announced that its CEO Matt Gline will present at Guggenheim’s...

Conference call today at 8:00am ET VANCOUVER, British Columbia and CAMBRIDGE, Mass. and BASEL, Switzerland, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery...

Roivant’s newly launched subsidiary, Hemavant, entered into a licensing agreement with Eisai Co., Ltd. for exclusive global rights to the investigational agent RVT-2001, a potential first-in-class...

Quarterly investor call and webcast scheduled for Monday, February 14 at 8:00 a.m. ETRoivant will also present at the SVB Leerink Global Healthcare Conference in February, and the Truist AI Symposium...

BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) today announced that its CEO Matt Gline will present at two upcoming...

Roivant will develop RVT-2001 for the treatment of transfusion-dependent anemia in patients with lower-risk myelodysplastic syndromesRoivant JPM presentation scheduled for Monday, January 10, at 2:15...

Roivant began trading on Nasdaq under “ROIV”; cash balance increased to $2.5 billion.Dermavant announced final results from the Phase 3 PSOARING 3 long-term extension study of tapinarof in patients...